The vector of anti-NY-ESO-1 T cell receptor (TCR) is constructed for the engineering of T cell to target Human NY-ESO-1. The T cells are genetically modified through transduction with a lentiviral vector expressing NY-ESO-1-specific T cell receptor. And the vector product was designed for the treatment of Melanoma, breast cancer, lung cancer, prostate cancer, thyroid cancer, ovarian cancer, or synovial cell sarcoma..
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
|TCR-L210||Human anti-NY-ESO-1 T cell receptor (1G4), pCDTCR1|
|TCR-L235||Human anti-NY-ESO-1 T cell receptor (JM), pCDTCR1|
|TCR-L209||Human anti-NY-ESO-1 T cell receptor (1G4), pCDTCR1|
|VP-TCR-C073||Lenti-NY-ESO-1 T cell receptor (5B8) Viral Particle|
|TCR-L157||Human anti-NY-ESO-1 T cell receptor (TCRCD8-NY#15), pCDTCR1|
|CAR-T-2-M323-CZ||Anti-NY-ESO-1 scFv h(b2c-CD3ζ) CART, pCDCAR1|
|VP-TCR-C056||Lenti-NY-ESO-1 T cell receptor (TCRCD8-NY#5) Viral Particle|
|TCR-L154||Human anti-NY-ESO-1 T cell receptor (TCRCD8-NY#8), pCDTCR1|
|VP-TCR-C065||Lenti-NY-ESO-1 T cell receptor (TCRCD4-NY#7) Viral Particle|
|TCR-L162||Human anti-NY-ESO-1 T cell receptor (TCRCD4-NY#10), pCDTCR1|
Copyright © 2007 - 2017 Creative Biolabs. All Rights Reserved